Page 1

+ + + + + + + + BIOVICA + + + + + + ● + + SEK 000s Net sales Operating profit ( loss ) Profit ( loss ) for the period Earnings per share , after dilution + + + + Significant events during the first quarter + + + + + + + DiviTum TKa approaching FDA approval Q1 Interim report May - July 2021/2022 Q1 21/22 381 -12,238 -12,225 -0.43 + + + + -8,665 -8,374 -0.36 + + + + Q1 20/21 May - April 20/21 340 2,077 -40,181 -39,482 -1.39 + + https://tv.streamfabriken.com/biovica-international-q1-2021-2022 The PROMIX breast cancer study at Karolinska University Hospital has been published in the scientific journal , ESMO Open . The DiviTum ⓇTKa budget impact model shows potential for savings of three times the cost of DiviTum ⓇTKa . Biovica strengthens its management team by appointing a new commercial manager and a new quality and regulatory manager . Significant events after the end of the period Results presented for DiviTum ⓇTKa showing its prognostic and predictive capabilities for patients with metastatic skin cancer who are undergoing immunotherapy . Biovica has strengthened its management team with the addition of Warren Cresswell , President Americas , with responsibility for the launch of DiviTum ⓇTKa in the USA . + + Audiocast : When : 2 September 2021 at 10:00 AM CET Where : Phone numbers : SE : +46850558365 , DK : +4578150108 , UK : +443333009262 , US : +16467224902 Broadcast language : in English + + + + ) ( + ) ( + ) + + + + + +